Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases

Table 3 Distribution of chemotherapy administration, efficacy and toxicity in the three different patient’s groups

Characteristic	Adjunctive chemotherapy group (n = 13)	Primary FOLFIRI group (n = 10)	Primary FOLFOX group (n = 8)
Chemotherapy cycles given per patient
Range	3-6	2-12	3-12
Median	6	7	8
Response to chemotherapy (%)
CR/PR	-	2 (20.0)	2 (25.0)
SD	-	5 (50.0)	5 (62.5)
PD	-	2 (20.0)	1 (12.5)
Not applicable	13	1 (10.0)	0
Discontinuation of chemotherapy
Due to death	1	1	0
Due to toxicity	1	0	1

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; FOLFIRI: 5-fluorouracil, leucovorin and irinotecan combination; FOLFOX: 5-fluorouracil, leucovorin and oxaliplatin combination; RFA: Radiofrequency ablation.